{
    "2021-09-14": [
        [
            {
                "time": "",
                "original_text": "大摩：上调上海医药(2607.HK)目标价至22港元 评级“增持”",
                "features": {
                    "keywords": [
                        "大摩",
                        "上海医药",
                        "目标价",
                        "上调",
                        "增持"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "上海医药发布公告 子公司上药禾丰收国家药监局药品注册证书",
                "features": {
                    "keywords": [
                        "上海医药",
                        "公告",
                        "子公司",
                        "上药禾丰",
                        "药品注册证书",
                        "国家药监局"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "大摩：维持上海医药(02607)“增持”评级 目标价上调7%至22港元",
                "features": {
                    "keywords": [
                        "大摩",
                        "上海医药",
                        "目标价",
                        "上调",
                        "7%",
                        "增持"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}